Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.
- This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.
- We look forward to the results of the ORIGIN trial which will be a first for the field.
- Subjects were randomized 2:2:1:2 to atacicept 150 mg, atacicept 75 mg, atacicept 25 mg, or matching placebo.
- Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study.